---
title: "Loss to Follow-Up in Kaposi Sarcoma at Ocean Road Cancer Institute: Competing-Risks Analysis"
id: "medrxiv-6-loss-to-follow-up-among-patients-with-kaposi-sarcoma-at-the-ocean-road-cancer"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-loss-to-follow-up-among-patients-with-kaposi-sarcoma-at-the-ocean-road-cancer"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1?rss=1"
published_at: "2026-08-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Loss to Follow-Up in Kaposi Sarcoma at Ocean Road Cancer Institute: Competing-Risks Analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-loss-to-follow-up-among-patients-with-kaposi-sarcoma-at-the-ocean-road-cancer
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1?rss=1)
- **Published At:** 2026-08-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective cohort at the Ocean Road Cancer Institute (ORCI), Tanzania, evaluated **loss to follow-up (LTFU)** among 251 patients with **Kaposi sarcoma (KS)** treated from January 2021 to December 2023, treating death as a competing event. - Patient mix: 214 (85.3%) epidemic (HIV-associated) KS and 37 (14.7%) endemic (non-HIV-associated) KS; 62.2% male. - Cumulative incidence of LTFU accounting for death: 27.6% (95% CI 22.0–33.1) at 6 months; 36.4% (95% CI 30.5–42.4) at 12 months; 43.3% (95% CI 37.2–49.4) at 18 months; and 46.6% (95% CI 40.4–52.7) at 24 months. - Multivariable Fine–Gray subdistribution hazards regression identified three factors independently associated with lower LTFU risk: absence of oral involvement (aSHR 0.37), having a reachable telephone contact (aSHR 0.54), and receiving initial **chemotherapy** rather than radiotherapy (aSHR 0.44). - Authors highlight that nearly half of KS patients were LTFU by two years, which hampers reliable outcome assessment and may bias survival and mortality estimates if death is not treated as a competing risk. - Recommendations from the study include strengthening retention strategies, maintaining reliable patient contact information, and implementing routine phone-based follow-up to improve continuity of care and cancer surveillance in resource-limited settings. - Ethical approvals were obtained from the Muhimbili University of Health and Allied Sciences Institutional Research and Ethics Committee (MUHAS IRB). Data are available from the corresponding author on request.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=1rDI5we8y5SvNd_VZy1sa5joF96gcPV5CAKFi6C_r2A-1787969449.176648-1.2.1.1-6suZP4bLj_ukWmupKck2z24.NgIbZfho4KGF0dT6pL21oTsRoyx_fmSX2uHGLYQB) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Loss to Follow-Up Among Patients with Kaposi Sarcoma at the Ocean Road Cancer Institute, Tanzania: A Fine–Gray Competing-Risks Analysis of Death as a Competing Event [ View ORCID Profile](http://orcid.org/0000-0002-9083-4302)Emmanuel L. Lugina, Chahcha Jos Mwita, Tumaini Lugina Nyamhanga, Salum J Lidenge, John R Ngowi, Crispin Lugina Kahesa, [ View ORCID Profile](http://orcid.org/0000-0002-4256-1530)Charles Wood, Julius David Mwaiselage doi: https://doi.org/10.64898/2026.08.26.26361391 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Emmanuel L. Lugina 1 Muhimbili University of Health and Allied Sciences School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emmanuel%2B%2BL.%2BLugina%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lugina%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEmmanuel%2B%2BL.%2BLugina%2B) * [ORCID record for Emmanuel L. Lugina](http://orcid.org/0000-0002-9083-4302 "Open in new tab") * For correspondence: elugina@yahoo.com Chahcha Jos Mwita 2 MUHAS: Muhimbili University of Health and Allied Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chahcha%2B%2BJos%2BMwita%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mwita%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChahcha%2B%2BJos%2BMwita%2B) Tumaini Lugina Nyamhanga 3 Muhimbili University of Health and Allied Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tumaini%2B%2BLugina%2BNyamhanga%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nyamhanga%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATumaini%2B%2BLugina%2BNyamhanga%2B) Salum J Lidenge 2 MUHAS: Muhimbili University of Health and Allied Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Salum%2B%2BJ%2BLidenge%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lidenge%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASalum%2B%2BJ%2BLidenge%2B) John R Ngowi 4 Muhimbili University College of Health Sciences: Muhimbili University of Health and Allied Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=John%2B%2BR%2BNgowi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ngowi%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJohn%2B%2BR%2BNgowi%2B) Crispin Lugina Kahesa 5 Ocean Road Cancer Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Crispin%2B%2BLugina%2BKahesa%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kahesa%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACrispin%2B%2BLugina%2BKahesa%2B) Charles Wood 6 LSU Health Sciences Center New Orleans: Louisiana State University Health Sciences Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Charles%2BWood%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wood%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACharles%2BWood%2B) * [ORCID record for Charles Wood](http://orcid.org/0000-0002-4256-1530 "Open in new tab") Julius David Mwaiselage 4 Muhimbili University College of Health Sciences: Muhimbili University of Health and Allied Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julius%2B%2BDavid%2BMwaiselage%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mwaiselage%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulius%2B%2BDavid%2BMwaiselage%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1288134/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1288134/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1288134/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1288134/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1288134/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Purpose Kaposi sarcoma (KS) remains one of the most common HIV-associated malignancies in sub-Saharan Africa (SSA). While loss to follow-up (LTFU) has been well documented among KS patients managed within HIV primary care, little is known about retention after patients transition into specialized oncology care, where treatment pathways, toxicities, costs, and follow-up schedules differ substantially. Because LTFU is unlikely to occur at random, patients who disengage from care may differ systematically from those retained with respect to disease severity, treatment response, and mortality risk, potentially biasing survival estimates and underestimating cancer-related mortality. This study aimed to estimate the cumulative incidence of LTFU among patients with KS receiving care at Tanzania’s national cancer referral center, accounting for death as a competing event, and to identify factors associated with LTFU. Methods This retrospective cohort study included 251 patients with KS treated at Ocean Road Cancer Institute (ORCI) between January 2021 and December 2023. The primary outcome was LTFU, with death treated as a competing event. Cumulative incidence of LTFU at 6, 12, 18, and 24 months was estimated using the cumulative incidence function. Predictors of LTFU were assessed using univariable and multivariable Fine-Gray subdistribution hazards regression. Results Among 251 patients, 214 (85.3%) had epidemic (HIV-associated) KS and 37 (14.7%) had endemic (non-HIV-associated) KS. Males accounted for 62.2%. Accounting for death as a competing event, the cumulative incidence of LTFU was 27.6% (95% CI, 22.0–33.1) at 6 months, 36.4% (95% CI, 30.5–42.4) at 12 months, 43.3% (95% CI, 37.2–49.4) at 18 months, and 46.6% (95% CI, 40.4–52.7) at 24 months. In multivariable Fine–Gray regression, absence of oral involvement (adjusted subdistribution hazard ratio [aSHR], 0.37), reachable telephone contact (aSHR, 0.54), and initial chemotherapy rather than radiotherapy (aSHR, 0.44) were independently associated with lower risk of LTFU. Conclusion Nearly half of patients with KS were LTFU within two years, substantially limiting reliable assessment of cancer outcomes in this setting. Strengthening retention strategies, including maintaining reliable patient contact information and implementing routine phone-based follow-up, may offer feasible, scalable approaches to improve continuity of care, enhance survival monitoring, and strengthen cancer surveillance in resource-limited settings. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval for this study was obtained from the Muhimbili University of Health and Allied Sciences Institutional Research and Ethics Committee (MUHAS IRB). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.06.23.26356379v2 "Model-Specific Disruption of Demographic Prediction in Retinal Fundus Images")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.25.26360651v1 "A Spanish grammaticality judgment task for neurodegenerative diseases: inflectional, transitivity, and word order comprehension in PPA and Alzheimer's Disease") Posted August 28, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/28/2026.08.26.26361391.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.26.26361391v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/28/2026.08.26.26361391.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Loss to Follow-Up Among Patients with Kaposi Sarcoma at the Ocean Road Cancer Institute, Tanzania: A Fine–Gray Competing-Risks Analysis of Death as a Competing Event Emmanuel L. Lugina, Chahcha Jos Mwita, Tumaini Lugina Nyamhanga, Salum J Lidenge, John R Ngowi, Crispin Lugina Kahesa, Charles Wood, Julius David Mwaiselage medRxiv 2026.08.26.26361391; doi: https://doi.org/10.64898/2026.08.26.26361391 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26361391v1%26text%3DLoss%2520to%2520Follow-Up%2520Among%2520Patients%2520with%2520Kaposi%2520Sarcoma%2520at%2520the%2520Ocean%2520Road%2520Cancer%2520Institute%252C%2520Tanzania%253A%2520A%2520Fine%25E2%2580%2593Gray%2520Competing-Risks%2520Analysis%2520of%2520Death%2520as%2520a%2520Competing%2520Event "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26361391v1%26t%3DLoss%2520to%2520Follow-Up%2520Among%2520Patients%2520with%2520Kaposi%2520Sarcoma%2520at%2520the%2520Ocean%2520Road%2520Cancer%2520Institute%252C%2520Tanzania%253A%2520A%2520Fine%25E2%2580%2593Gray%2520Competing-Risks%2520Analysis%2520of%2520Death%2520as%2520a%2520Competing%2520Event "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26361391v1%26title%3DLoss%2520to%2520Follow-Up%2520Among%2520Patients%2520with%2520Kaposi%2520Sarcoma%2520at%2520the%2520Ocean%2520Road%2520Cancer%2520Institute%252C%2520Tanzania%253A%2520A%2520Fine%25E2%2580%2593Gray%2520Competing-Risks%2520Analysis%2520of%2520Death%2520as%2520a%2520Competing%2520Event%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26361391v1%26title%3DLoss%2520to%2520Follow-Up%2520Among%2520Patients%2520with%2520Kaposi%2520Sarcoma%2520at%2520the%2520Ocean%2520Road%2520Cancer%2520Institute%252C%2520Tanzania%253A%2520A%2520Fine%25E2%2580%2593Gray%2520Competing-Risks%2520Analysis%2520of%2520Death%2520as%2520a%2520Competing%2520Event "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.26.26361391) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.26.26361391v1&count=horizontal&via=&text=Loss%20to%20Follow-Up%20Among%20Patients%20with%20Kaposi%20Sarcoma%20at%20the%20Ocean%20Road%20Cancer%20Institute%2C%20Tanzania%3A%20A%20Fine%E2%80%93Gray%20Competing-Risks%20Analysis%20of%20Death%20as%20a%20Competing%20Event&counturl=www.medrxiv.org/content/10.64898/2026.08.26.26361391v1 "Tweet This") ## Subject Area * [Epidemiology ](https://www.medrxiv.org/collection/epidemiology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (612) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (893) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (325) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4754) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (640) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1610) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15810) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6972) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1052) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4961) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1423) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1731) * [Hematology](https://www.medrxiv.org/collection/hematology) (578) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1330) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16230) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1158) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (661) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (718) * [Neurology](https://www.medrxiv.org/collection/neurology) (7167) * [Nursing](https://www.medrxiv.org/collection/nursing) (362) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1072) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1226) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (999) * [Oncology](https://www.medrxiv.org/collection/oncology) (3563) *
## Related Clinical Research

- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Higher dietary antioxidants linked to lower odds of cervical cancer in NHANES analysis](https://medichelpline.com/clinical-feed/medical-news-today-1-study-finds-link-between-antioxidant-rich-diets-and-lower-cervical-cancer-odds.md)
- [Handshake in Medicine: Why Clinicians Should Reconsider Shaking Hands](https://medichelpline.com/clinical-feed/stat-news-4-opinion-medicine-stopped-shaking-hands-we-should-start-again.md)
- [HHS RFI Reveals Clues to RFK Jr. and Trump’s Proposed Vaccine Policy Changes](https://medichelpline.com/clinical-feed/stat-news-0-stat-hhs-document-offers-new-clues-to-kennedy-s-vaccine-plans.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.